Foamix’s Amzeeq (topical minocycline) Receives the US FDA’s Approval for Moderate to Severe Acne

 Foamix’s Amzeeq (topical minocycline) Receives the US FDA’s Approval for Moderate to Severe Acne

Foamix’s Amzeeq (Topical Minocycline) Receives the US FDA’s Approval for Moderate to Severe Acne

Shots:

  • The approval is based on P-III clinical studies evaluating Amzeeq (topical foam, 4%) versus vehicle in 2,418 patients aged ≥9yrs. with inflammatory lesions of non-nodular moderate to severe acne vulgaris
  • The P-III studies resulted in improvement in reduction of inflammatory lesions and improvement in IGA treatment success defined as score of 0 (“clear”) or 1 (“almost clear”) and at least a two-point decrease from baseline, well-tolerated with no AEs
  • Amzeeq (FMX101) is the first topical minocycline to be approved by the FDA for any condition and is indicated to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients with its anticipated availability in the US in Jan’2020

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post